Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M.

Creative Proteomics Launches State-of-the-Art Peptide Sequencing Service to Advance Proteomics Research

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

HERMES PHARMA announces €25 million investment to bolster capacity

HERMES PHARMA, the leading expert in user-friendly oral dosage forms, has announced it will invest €25 million to further bolster its manufacturing capabilities.

Announcing Kivo GO: An intuitive DMS to accelerate speed-to-market for life sciences

Kivo today introduced Kivo GO, a unified platform for emerging life sciences teams who need to work together efficiently across all functions while maintaining compliance and security.

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Discovery Park selects 13 start-ups to join Discovery Spark life science programme

Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Sygnature Discovery successfully identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation

Optibrium Releases Powerful Metabolism Prediction Capability in Next Generation StarDrop Software

Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.

DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

Bio-IT World Europe will convene in London 29-30 November 2023 to foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine.

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

Health Plan of San Joaquin Selects ZeOmega to Elevate Complete Care Management

Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide. HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.